Our pipeline
Innovation that advances cancer care
Seagen is developing a new generation of targeted, empowered treatments to advance cancer care. We’ve designed our pipeline with patients in mind, focusing on therapies that have the potential to address significant unmet medical needs.
The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.
Program
Phase
R/R Diffuse large B-Cell lymphoma
ECHELON-3: + lenalidomide, rituximab
1L Hodgkin lymphoma (HL)
+ nivolumab, doxorubicin and dacarbazine
1L HL or PTCL (unfit for combination chemotherapy)
Monotherapy
R/R HL and PTCL
Retreatment
R/R HL (pediatrics)
CheckMate 744: + nivolumab
1L PTCL (< 10% CD30 expression)
+ cyclophosphamide, doxorubicin and prednisone
R/R Metastatic solid tumors
+pembrolizumab post PD-1
1L untreated locally advanced or metastatic urothelial cancer
EV-302/KEYNOTE-A39: + pembrolizumab vs chemotherapy alone
Perioperative muscle invasive bladder cancer
KEYNOTE-905/ EV-303: + pembrolizumab, cisplatin ineligible
Perioperative muscle invasive bladder cancer
KEYNOTE-B15/ EV-304: + pembrolizumab, cisplatin eligible
Locally advanced or malignant metastatic solid tumors
EV-202: Monotherapy
Locally advanced or metastatic urothelial cancer*
EV-103/KEYNOTE-869: +/- pembrolizumab
Perioperative muscle invasive bladder cancer
EV-103/KEYNOTE-869: +/- pembrolizumab
BCG unresponsive non-muscle invasive bladder cancer
EV-104: intravesical EV
1L/2L metastatic HER2+ breast cancer
HER2CLIMB-02: + T-DM1
Adjuvant high risk HER2+ breast cancer
COMPASSHER2 RD: +T-DM1**
1L maintenance HER2+ metastatic breast cancer
HER2CLIMB-05: + trastuzumab and pertuzumab
1L HER2+ metastatic colorectal cancer
MOUNTAINEER-03: + trastuzumab and mFOLFOX6
2L HER2+ metastatic breast cancer
HER2CLIMB-04: + trastuzumab deruxtecan
R/R HER2+ metastatic colorectal cancer†*
MOUNTAINEER: + trastuzumab
2L HER2+ gastroesophageal cancer
MOUNTAINEER-02: + trastuzumab, ramucirumab and chemotherapy
Metastatic solid tumors HER2 alterations
+ trastuzumab
1L HER2+ metastatic gastrointestinal cancers
+ trastuzumab +/- pembrolizumab +/- FOLFOX or CAPOX
**The trial is being conducted by the Alliance for Clinical Trials in Oncology
1L/2L Recurrent or metastatic cervical cancer
innovaTV 205: + other anti-cancer agents
2L/3L Metastatic/recurrent cervical cancer
innovaTV 301: Monotherapy vs. chemotherapy
R/R Metastatic solid tumors
innovaTV 207: Monotherapy or + other anti-cancer agents
1L Metastatic triple-negative breast cancer
+ pembrolizumab
R/R Metastatic solid tumors
Monotherapy
R/R Metastatic breast cancer
Monotherapy
In addition to the above programs, our clinical pipeline includes disitamab vedotin, an antibody-drug conjugate that we recently licensed from RemeGen. Disitamab vedotin has potential across multiple HER2-expressing solid tumors, including urothelial, breast and gastric cancers.
1L=frontline/first-line, 2L=second-line, R/R=relapsed/refractory, PTCL=peripheral T-cell lymphoma.
*Enrollment Complete
†Pivotal Trial
‡Top-line Data Reported
Request additional information
Request additional information about an investigational therapy or report an adverse event.